Sanofi India Ltd
Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.[1]
- Market Cap ₹ 9,132 Cr.
- Current Price ₹ 3,965
- High / Low ₹ 6,718 / 3,951
- Stock P/E 20.7
- Book Value ₹ 374
- Dividend Yield 2.95 %
- ROCE 49.2 %
- ROE 47.1 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company's working capital requirements have reduced from 27.6 days to 20.4 days
Cons
- Stock is trading at 10.6 times its book value
- Debtor days have increased from 32.9 to 41.7 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2023 | Dec 2024 | |
|---|---|---|
| 1,996 | 2,013 | |
| 1,508 | 1,522 | |
| Operating Profit | 488 | 491 |
| OPM % | 24% | 24% |
| 317 | 78 | |
| Interest | 2 | 2 |
| Depreciation | 36 | 37 |
| Profit before tax | 767 | 531 |
| Tax % | 21% | 22% |
| 603 | 413 | |
| EPS in Rs | 262.13 | 179.70 |
| Dividend Payout % | 64% | 65% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -25% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -5% |
| 3 Years: | 4% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 47% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Equity Capital | 23 | 23 |
| Reserves | 992 | 838 |
| 19 | 19 | |
| 681 | 732 | |
| Total Liabilities | 1,715 | 1,612 |
| 315 | 312 | |
| CWIP | 16 | 18 |
| Investments | 0 | 0 |
| 1,384 | 1,281 | |
| Total Assets | 1,715 | 1,612 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2023 | Dec 2024 | |
|---|---|---|
| 230 | 462 | |
| 38 | -180 | |
| -878 | -392 | |
| Net Cash Flow | -610 | -111 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Debtor Days | 24 | 42 |
| Inventory Days | 254 | 186 |
| Days Payable | 112 | 151 |
| Cash Conversion Cycle | 167 | 77 |
| Working Capital Days | 35 | 20 |
| ROCE % | 49% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
4h - Video of investors/analysts call (26 Feb 2026) on FY 2025 results uploaded on company website.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
1d - Annual Secretarial Compliance Report for year ended 31 Dec 2025 by Parikh & Associates.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1d - Copies of the Newspaper Publication of Financial Results for the quarter and year ended 31st December, 2025 of the Company published on 26th February 2026, …
-
Announcement under Regulation 30 (LODR)-Investor Presentation
1d - Will be made at the investor call.
-
Announcement under Regulation 30 (LODR)-Resignation of Director
2d - Approved FY2025 audited results; final dividend Rs48/share (total Rs123); appointed Kesari and Chakraborty; Hrosz resigned.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025Transcript PPT REC
-
May 2024Transcript PPT
-
Feb 2024TranscriptPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Nov 2023TranscriptPPT
-
May 2023TranscriptPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Mar 2021TranscriptAI SummaryPPT
Parent Company[1]
Sanofi Global and its 100% subsidiary - Hoechst GmbH, are the shareholders of Sanofi India and together hold 60.40%. Company's follows parent company's financial year hence, Financial year is same as Calender Year.